603127.SH
昭衍新药
SSE · Healthcare · Medical - Diagnostics & Research · CN
CNY 46.39
−5.85%Margins
Gross margin
19.3%
EBITDA margin
27.8%
EBIT margin
32.3%
Net margin
29.4%
FCF margin
2.4%
5.8%
Return on equity
4.9%
Return on assets
6.4%
Return on invested capital
0.17x
Asset turnover
CNY 507.0M
Cash from operations
—
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026